Sermorelin vs CJC-1295 at a glance
Sermorelin vs CJC-1295 comes down to one modification: an albumin-binding linker that turns a peptide with a plasma half-life measured in minutes into one measured in days. Both compounds are synthetic analogues of the first 29 amino acids of growth hormone-releasing hormone (GHRH), and both activate the same pituitary receptor. What separates them is how long each one survives in circulation before it is degraded, and that single variable changes almost everything about how each is used in a research protocol.
Sermorelin carries the native GHRH(1-29) sequence with no half-life-extending chemistry. CJC-1295, in its full form, adds a Drug Affinity Complex (DAC) that binds covalently to serum albumin. The table below summarizes the practical differences.
| Feature | Sermorelin | CJC-1295 (with DAC) |
|---|---|---|
| Backbone | Native GHRH(1-29)-NH2 | Modified GRF(1-29) plus DAC linker |
| Plasma half-life | About 11 to 12 minutes | 5.8 to 8.1 days |
| Albumin binding | None | Covalent, at Cys34 |
| GH elevation window per dose | Roughly 3 hours | 6 days or more |
| Human RCT data | Yes, pediatric GHD trials | Yes, healthy-adult PK study; phase 2 lipodystrophy trial terminated |
| FDA history | Approved 1997 as Geref, discontinued 2008 | Never submitted for approval |
Same backbone, one added linker
Both peptides descend from the same 29-residue fragment of endogenous GHRH, the minimum sequence that retains full receptor-binding activity against the pituitary GHRH receptor (GHRH-R). Sermorelin is that fragment, amidated at the C-terminus, with no further changes.
CJC-1295 starts from a modified version of the same backbone, carrying amino acid substitutions that resist cleavage by dipeptidyl peptidase-IV (DPP-IV), the enzyme responsible for most of the peptide's natural degradation. On its own, this DPP-IV-resistant backbone (sold separately as modified GRF 1-29, or "CJC-1295 without DAC") has a half-life of roughly 30 minutes. The DAC addition is a separate step: a maleimidopropionic acid group attached to the peptide's C-terminus that reacts with the free thiol on cysteine-34 of circulating serum albumin, forming a stable covalent bond within minutes of subcutaneous injection.
Jette and colleagues described this chemistry in a 2005 paper in Endocrinology (Jette et al., Endocrinology, 2005), testing maleimide-modified hGRF(1-29)-albumin conjugates in rats. The lead compound, later named CJC-1295, produced a 4-fold increase in GH area under the curve over a 2-hour window compared to unmodified hGRF(1-29), and remained detectable in circulation beyond 24 hours. Once bound to albumin, a large, slowly cleared plasma protein, the peptide is protected from renal filtration and enzymatic attack, which is the physical basis for the multi-day half-life measured later in humans.
What the pharmacokinetic data actually show
The clearest illustration of how much a single amino acid substitution matters comes from Soule and colleagues, who compared native GHRH(1-29)-NH2 to a D-Ala2-substituted analogue under continuous intravenous infusion in 10 healthy men (Soule et al., J Clin Endocrinol Metab, 1994). The native peptide cleared at 39.7 mL/kg/min with a half-life of 4.3 minutes. Replacing alanine at position 2 with its D-isomer, which blocks the DPP-IV cleavage site, dropped clearance to 21 mL/kg/min and extended the half-life to 6.7 minutes. That single substitution roughly doubled residence time, and D-Ala2 protection is one of the modifications carried forward into CJC-1295's own backbone.
An earlier study by Rafferty and colleagues had already shown that DPP-IV resistance alone does not solve the pharmacokinetic problem (Rafferty et al., Peptides, 1988). Testing a series of D-amino acid GRF(1-29)-amide analogues, they found half-lives clustered in a 4.7- to 7.4-minute range, with subcutaneous bioavailability of only 4.6 to 7.2 percent regardless of the substitution pattern. Backbone protection buys minutes, not days. Reaching a half-life measured in days required the separate step of attaching the peptide to a long-lived plasma protein, which is what the DAC chemistry does.
Human data for CJC-1295 with DAC comes from Teichman and colleagues, who ran two randomized, double-blind, placebo-controlled ascending-dose trials in healthy adults aged 21 to 61 (Teichman et al., J Clin Endocrinol Metab, 91(3):799, 2006). A single subcutaneous injection raised mean plasma GH 2- to 10-fold for 6 days or more and raised IGF-1 1.5- to 3-fold for 9 to 11 days. Repeated dosing over 28 days produced cumulative elevation of both hormones, consistent with the 5.8- to 8.1-day half-life the authors estimated from the pharmacokinetic data. Our CJC-1295 and ipamorelin research overview covers this trial in more depth, including tolerability findings.
Growth hormone response: a single pulse vs sustained elevation
The functional consequence of the half-life difference is the shape of the GH response curve. Sermorelin produces a discrete pulse: GH rises, peaks, and returns to baseline within a few hours of a single dose. CJC-1295 with DAC produces something closer to a sustained plateau that persists across multiple days from one injection.
Sermorelin's clinical evidence base comes from pediatric growth hormone deficiency trials, not from adult metabolic research. The pivotal multicenter study, run by an international study group and published in 1996, enrolled 110 previously untreated prepubertal children with GHD, 86 of whom were evaluable for efficacy, and treated them once daily at bedtime with subcutaneous sermorelin (Thorner et al., J Clin Endocrinol Metab, 1996). Mean height velocity rose from 4.1 to 8.0 cm per year at 6 months and held at 7.2 cm per year at 12 months, with 74 percent of the cohort classified as responders. That trial became part of the FDA approval package for Geref Pediatric.
No comparable pediatric or adult efficacy trial exists for CJC-1295. Its human dataset is pharmacokinetic and safety-focused, not outcome-focused, and the compound has never carried a therapeutic indication in any jurisdiction. A researcher choosing between the two based on published evidence is choosing between a well-characterized growth response in children (sermorelin) and a well-characterized hormone kinetics profile in healthy adults (CJC-1295), which are not directly comparable endpoints.
Trial history and why neither reached the market as a long-term therapy
Sermorelin's commercial run ended for reasons unrelated to the science. Serono Laboratories marketed it as Geref, approved by the FDA in 1997 for pediatric GHD and pituitary function testing. The manufacturer discontinued the product in 2008, a withdrawal the FDA later confirmed was for commercial reasons, not for safety or effectiveness concerns. Recombinant human growth hormone had by then become the standard treatment for pediatric GHD, narrowing the market for a GHRH analogue that only stimulates the patient's own GH secretion.
CJC-1295 with DAC has a different history. Its only registered efficacy trial, a phase 2 study in HIV-associated visceral obesity sponsored by ConjuChem, enrolled 120 participants between December 2005 and September 2006 and is listed on ClinicalTrials.gov as terminated (NCT00267527). The registry entry does not specify a reason for termination, and no efficacy or safety results from that program were published in the peer-reviewed literature.
Development did not continue past that point, and CJC-1295 has never been submitted to a regulatory agency for approval. What remains in the literature is the earlier pharmacokinetic and safety data from Teichman's 2006 study in healthy volunteers, not evidence from a completed efficacy program.
Reconstitution and storage in a tropical research setting
Both compounds ship as lyophilized powder and follow the same general handling rules, with one difference driven by dosing frequency. Sermorelin's short half-life means research protocols typically call for once- or twice-daily dosing, so a reconstituted vial gets used up faster and spends less time in storage between doses. CJC-1295 with DAC is usually dosed weekly, so a reconstituted vial sits in the refrigerator longer, making stable cold storage and minimizing freeze-thaw cycles more consequential for that compound specifically.
In Bali, Jakarta, or other Indonesian research settings where ambient temperatures commonly exceed 30 degrees C, lyophilized vials of either compound should stay frozen or refrigerated until the moment of reconstitution, with only brief room-temperature exposure during handling. Our reconstitution guide covers the bacteriostatic water method step by step, and the sermorelin research overview has compound-specific stability notes. Use the dosing calculator to convert vial mass and diluent volume into a working concentration once a reconstitution plan is set.
Choosing between them for a research design
The choice tracks the research question, not a general preference for one compound over the other. A protocol built around measuring an acute, time-locked GH pulse, such as a stimulation test or a short pharmacodynamic window, matches sermorelin's minutes-long half-life and the extensive pediatric dosing literature behind it. A protocol built around sustained GH and IGF-1 elevation across days, with less frequent dosing and fewer injection events to control for, matches the profile Teichman and colleagues measured for CJC-1295 with DAC.
Neither compound has a completed adult efficacy trial, and CJC-1295's only attempt at one ended in early termination with no published results. Both remain research-use peptides characterized by mechanism and pharmacokinetics rather than by clinical outcome data, and protocols should be designed with that distinction in mind. Compound listings for CJC-1295 and ipamorelin are available in the Zurich Biotech research catalog.